Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074
Debt
Debt-to-Equity RatioN/A
Current Ratio18.21
Quick Ratio18.21
Price-To-Earnings
Trailing P/E Ratio-3.05
Forward P/E Ratio-2.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.49 million
Price / Sales48.92
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book0.98
Profitability
EPS (Most Recent Fiscal Year)($1.51)
Net Income$-70,980,000.00
Net Margins-1,736.95%
Return on Equity-31.97%
Return on Assets-30.64%
Miscellaneous
Employees82
Outstanding Shares47,750,000
Market Cap$220.14
Chimerix (NASDAQ:CMRX) Frequently Asked Questions
What is Chimerix's stock symbol?
Chimerix trades on the NASDAQ under the ticker symbol "CMRX."
How were Chimerix's earnings last quarter?
Chimerix Inc (NASDAQ:CMRX) posted its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.01. The biopharmaceutical company had revenue of $0.79 million for the quarter, compared to analysts' expectations of $1.12 million. Chimerix had a negative net margin of 1,736.95% and a negative return on equity of 31.97%. View Chimerix's Earnings History.
When is Chimerix's next earnings date?
What price target have analysts set for CMRX?
3 equities research analysts have issued 12 month price targets for Chimerix's stock. Their forecasts range from $6.00 to $10.00. On average, they expect Chimerix's stock price to reach $8.00 in the next year. This suggests a possible upside of 73.9% from the stock's current price. View Analyst Ratings for Chimerix.
What is the consensus analysts' recommendation for Chimerix?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Chimerix stock?
Here are some recent quotes from research analysts about Chimerix stock:
- 1. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (7/17/2018)
- 2. HC Wainwright analysts commented, "We think this announcement bodes well for the development and potential approval for brincidofovir for smallpox. As a reminder, oral brincidofovir is being developed for smallpox under the FDA’s Animal Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. Results from a study of brincidofovir in a rabbit model of smallpox showed improved survival, even when treatment was initiated during the course of disease. In the pivotal Phase 3 study for the treatment of smallpox conducted in the rabbitpox model, brincidofovir achieved statistically significant (p<0.05) reductions in mortality in brincidofovir treated animals in comparison to placebo group."" (6/7/2018)
Who are some of Chimerix's key competitors?
Some companies that are related to Chimerix include Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), AC Immune (ACIU), Amarin (AMRN), Rocket Pharmaceuticals (RCKT), Homology Medicines (FIXX), Inflarx (IFRX), Amphastar Pharmaceuticals (AMPH), Eidos Therapeutics (EIDX), AMAG Pharmaceuticals (AMAG), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY), Adamas Pharmaceuticals (ADMS), NuCana (NCNA) and GlycoMimetics (GLYC).
Who are Chimerix's key executives?
Chimerix's management team includes the folowing people:
- Dr. M. Michelle Berrey, Pres, CEO & Director (Age 51)
- Mr. Timothy W. Trost, Sr. VP, CFO, Principal Accounting Officer & Corp. Sec. (Age 60)
- Ms. Linda M. Richardson, Chief Strategy & Commercial Officer (Age 54)
- Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 49)
- Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
Has Chimerix been receiving favorable news coverage?
News coverage about CMRX stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Chimerix earned a daily sentiment score of 0.08 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 44.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Chimerix's major shareholders?
Chimerix's stock is owned by many different of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.49%). Company insiders that own Chimerix stock include Ernest Mario, John M Leonard, Linda M Richardson and M Michelle Berrey. View Institutional Ownership Trends for Chimerix.
Which major investors are buying Chimerix stock?
How do I buy shares of Chimerix?
Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chimerix's stock price today?
One share of CMRX stock can currently be purchased for approximately $4.60.
How big of a company is Chimerix?
Chimerix has a market capitalization of $220.14 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.
How can I contact Chimerix?
Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]
MarketBeat Community Rating for Chimerix (NASDAQ CMRX)
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
